drugset / Trial / NCT04425031

Handling Oxygenation Targets in COVID-19

NCT04425031

RandomizedParallel-groupSingle-blindPrevention

Summary

Patients with COVID-19 and hypoxaemic respiratory failure and admitted to the intensive care unit (ICU) are treated with supplementary oxygen as a standard. However, quality of quantity evidence regarding this practise is low. The aim of the HOT-COVID trial is to evaluate the benefits and harms of two targets of partial pressure of oxygen in arterial blood (PaO2) in guiding the oxygen therapy in acutely ill adult COVID-19 patients with hypoxaemic respiratory failure at ICU admission.

Timeline

Start
2020-08-25
Primary completion
2023-03-08
Completion
2024-03-08

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Oxygen Other / unclassified